Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
April 6, 2026
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
Where This Stands
Currently in_committee. The next step in the legislative lifecycle is Floor Vote.
Version history
Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.
View official text →The Frame
This legislation ensures the continuation of federal ALS research grants and regulatory programs through 2031, impacting the timeline for drug development and the availability of clinical trial data for patients and researchers.
Potentially affected actors named in the source documents. Mention is not a position.
ALS patients and families
The bill dictates the timeline and regulatory framework for research into therapies for their condition.
Pharmaceutical manufacturers
Companies conducting ALS clinical trials must share interim data with the FDA to qualify for grant renewals.
Food and Drug Administration
The agency is tasked with new reporting requirements and oversight duties regarding clinical trial data.
Current stage: in_committee.
Floor Vote.
Summary
Key Facts
- Extends the authorization of the Accelerating Access to Critical Therapies for ALS Act from 2026 to 2031.
- Requires the FDA to assess clinical trial enrollment data when reviewing grant renewal applications for investigational drugs.
- Mandates that manufacturers share interim clinical trial data with the FDA to facilitate grant renewal assessments.
- Expands the definition of 'phase 3' clinical trials to include combined phase 2/3 trials and planned trials not yet enrolling participants.
- Requires the FDA Commissioner to publish an updated action plan for ALS and other rare neurodegenerative diseases within one year of enactment.
- Requires the FDA to report on the implementation and outcomes of the 2022 Action Plan for Rare Neurodegenerative Diseases.
- Mandates a GAO report on the program's progress to be submitted to Congress within four years of enactment.
- Expresses a Sense of Congress that funds should be directly appropriated to carry out the Act's provisions.
Why It Matters
This legislation ensures the continuation of federal ALS research grants and regulatory programs through 2031, impacting the timeline for drug development and the availability of clinical trial data for patients and researchers.
Frequently Asked Questions
How long will this program be extended?
What new information must drug manufacturers provide?
When will the public see a report on these efforts?
News Coverage
Sponsors
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
Increased Data Transparency
The bill shifts from simple funding authorization to requiring active sharing of interim clinical trial data between manufacturers and the FDA.
Connected Entities
Analysis Score
0–100- Significance75How much this matters to a regular citizen
- Controversy10Intensity of disagreement among stakeholders
- Entertainment5Compellingness for a non-policy-wonk reader
- Buzz20Current news / social attention level
Publisher tools